Importance of CDK4/6 INHIBITORS
The addition of a CDK4/6i to ET is proven to reduce recurrence risk1,2
My disease had moved into my lymph nodes, so my doctor told me my cancer was at high risk of recurrence. She strongly recommended I start on a CDK4/6 inhibitor in addition to ET.
Jamie, a real patient diagnosed with HR+, HER2–, high-risk EBC
TREATMENT BARRIERS
Barriers often prevent patients with high-risk features from receiving the treatment they need—but they can be reduced
The right tools could help pave the way to better outcomes
Your patients have concerns around their treatment experienceHave a dialogue with your patients.
Consider asking questions like:
- "What are your concerns when you consider adding on another treatment?"
- "Now that you've completed active therapy, what is your greatest concern?"
- "Do you understand what having high-risk features may mean for you?"
There may be incorrect perceptions around which patients have high-risk features and require more treatmentEnsure you have the latest information when making treatment decisions
- Consider all the factors that can impact risk level and the possible benefits of treatment with a CDK4/6i along with ET
Patients may lack access to treatment resourcesProvide patients with support to help them better understand the goals of adjuvant treatment
My choice to follow my
Tina, a real patient diagnosed with HR+, HER2−, high-risk EBC
doctor's recommendation to add a CDK4/6 inhibitor to my ET was my personal
motivation to do everything I could to try to reduce the risk of recurrence.
CDK4/6i=cyclin-dependent kinase 4 and 6 inhibitor; EBC=early breast cancer; EHR=electronic health record; ET=endocrine therapy; HER2−=human epidermal growth factor receptor 2-negative; HR+=hormone receptor-positive.
References:1. Liu Y, Su J, Wu P, et al. Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: an updated systematic review and meta-analysis. Front Pharmacol. 2025;16:1564437. doi:10.3389/fphar.2025.1564437 2. Johnston S, Martin M, O’Shaughnessy J, et al. Ann Oncol. 2025; Epub (Incl Suppl Mat). doi:10.1016/j.annonc.2025.10.005
Your Privacy Choices